Janux Therapeutics (JANX) Net Income towards Common Stockholders: 2020-2025
Historic Net Income towards Common Stockholders for Janux Therapeutics (JANX) over the last 6 years, with Sep 2025 value amounting to -$24.3 million.
- Janux Therapeutics' Net Income towards Common Stockholders rose 13.35% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.9 million, marking a year-over-year decrease of 68.32%. This contributed to the annual value of -$69.0 million for FY2024, which is 18.36% down from last year.
- Per Janux Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$24.3 million for Q3 2025, which was up 28.19% from -$33.9 million recorded in Q2 2025.
- Janux Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$2.3 million for Q1 2021, and its period low was -$33.9 million during Q2 2025.
- For the 3-year period, Janux Therapeutics' Net Income towards Common Stockholders averaged around -$19.0 million, with its median value being -$17.5 million (2023).
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 757.17% in 2021, then soared by 65.96% in 2024.
- Over the past 5 years, Janux Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$13.4 million in 2021, then declined by 19.75% to -$16.1 million in 2022, then climbed by 26.81% to -$11.8 million in 2023, then slumped by 71.93% to -$20.2 million in 2024, then climbed by 13.35% to -$24.3 million in 2025.
- Its last three reported values are -$24.3 million in Q3 2025, -$33.9 million for Q2 2025, and -$23.5 million during Q1 2025.